TNFRSF25 and type 2 diabetes mellitus: Our results further emphasize the critical role of DR3 as a modulator of ILC2 effector functions, thus providing new insights into the role of DR3 in VAT-derived ILC2s and establishing DR3 agonist treatment as a promising and novel therapeutic option for prevention and treatment of T2DM.